A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4–ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is...

Descripción completa

Detalles Bibliográficos
Autores principales: Esfahani, Khashayar, Agulnik, Jason Scott, Cohen, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104550/
https://www.ncbi.nlm.nih.gov/pubmed/25101240
http://dx.doi.org/10.3389/fonc.2014.00174
_version_ 1782327268533600256
author Esfahani, Khashayar
Agulnik, Jason Scott
Cohen, Victor
author_facet Esfahani, Khashayar
Agulnik, Jason Scott
Cohen, Victor
author_sort Esfahani, Khashayar
collection PubMed
description The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4–ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors containing this genetic abnormality. In this mini review, we discuss the existing data on crizotinib as well as ongoing trials involving this medication. A brief overview of the known resistance mechanisms to crizotinib will also be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC.
format Online
Article
Text
id pubmed-4104550
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-41045502014-08-06 A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer Esfahani, Khashayar Agulnik, Jason Scott Cohen, Victor Front Oncol Oncology The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4–ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors containing this genetic abnormality. In this mini review, we discuss the existing data on crizotinib as well as ongoing trials involving this medication. A brief overview of the known resistance mechanisms to crizotinib will also be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC. Frontiers Media S.A. 2014-07-21 /pmc/articles/PMC4104550/ /pubmed/25101240 http://dx.doi.org/10.3389/fonc.2014.00174 Text en Copyright © 2014 Esfahani, Agulnik and Cohen. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Esfahani, Khashayar
Agulnik, Jason Scott
Cohen, Victor
A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
title A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
title_full A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
title_fullStr A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
title_full_unstemmed A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
title_short A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
title_sort systemic review of resistance mechanisms and ongoing clinical trials in alk-rearranged non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104550/
https://www.ncbi.nlm.nih.gov/pubmed/25101240
http://dx.doi.org/10.3389/fonc.2014.00174
work_keys_str_mv AT esfahanikhashayar asystemicreviewofresistancemechanismsandongoingclinicaltrialsinalkrearrangednonsmallcelllungcancer
AT agulnikjasonscott asystemicreviewofresistancemechanismsandongoingclinicaltrialsinalkrearrangednonsmallcelllungcancer
AT cohenvictor asystemicreviewofresistancemechanismsandongoingclinicaltrialsinalkrearrangednonsmallcelllungcancer
AT esfahanikhashayar systemicreviewofresistancemechanismsandongoingclinicaltrialsinalkrearrangednonsmallcelllungcancer
AT agulnikjasonscott systemicreviewofresistancemechanismsandongoingclinicaltrialsinalkrearrangednonsmallcelllungcancer
AT cohenvictor systemicreviewofresistancemechanismsandongoingclinicaltrialsinalkrearrangednonsmallcelllungcancer

Ejemplares similares